A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Public ClinicalTrials.gov record NCT05709444. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease to Assess the Efficacy in Reducing Urinary Protein and Maintaining Podocyte Density and Function
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.
Study identification
- NCT ID
- NCT05709444
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 16 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 25, 2022
- Primary completion
- Apr 25, 2024
- Completion
- Apr 25, 2024
- Last update posted
- Oct 16, 2024
2022 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Institute of Renal Research | Chula Vista | California | 91910 | — |
| California Institute of Renal Research DBA - Balboa Research | La Mesa | California | 91942 | — |
| Georgia Nephrology, LLC DBA -GA Nephrology Research Institute | Decatur | Georgia | 30030 | — |
| Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute | Lawrenceville | Georgia | 30046 | — |
| Brookview Hills Research Associates, LLC | Winston-Salem | North Carolina | 27103 | — |
| Northeast Research Center, LLC | Bethlehem | Pennsylvania | 18017 | — |
| Nephrotex Research Group | Dallas | Texas | 75231 | — |
| Prolator Clinical Research Center | Houston | Texas | 77030 | — |
| Clinical Advancement Center, PLLC | San Antonio | Texas | 78212 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Kidney Disease trials
Other public records listing Kidney Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07794631: Strategies to Transform Kidney Care and Improve Pursuit of Transplant Active, not recruiting
- NCT07426380: A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function Active, not recruiting
- NCT07760363: Pedal Pump Clinical Trial on Edema V1 Recruiting
- NCT06734234: A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease Active, not recruiting
- NCT07685886: MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes Not yet recruiting
- NCT04040959: Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05709444, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05709444 live on ClinicalTrials.gov.